Specific allergen immunotherapy is clinically effective and has benefit that extends beyond the treatment period (1). Unlike conventional pharmacotherapy, specific allergen immunotherapy is disease modifying and has been shown to prevent the development of asthma (2) and to reduce sensitizations to other allergens (3). Optimal treatment times vary based on allergen and therapeutic preparation, but in general terms, a course of 3 years therapy is regarded as optimal. Although there are no formal published data on the relationship between treatment time and duration of clinical response, it is widely held that clinical benefit will last for twice as long as the treatment period. Thus, treatment for 1 year results in additional benefit for the subsequent year, whereas treatment for 3 years will provide clinical benefit for a further 3 years. The lengthy duration of treatment, the frequent administration of allergen and the associated high frequency of allergic adverse events, which may be systemic and in some cases lifethreatening, have limited uptake of this form of therapy. These shortcomings are the result of the allergenicity of the preparations employed for therapy. These contain whole allergen molecules with intact B-cell epitopes that are readily able to crosslink specific IgE molecules on the surface of effector cells (Fig. 1). A number of strategies aimed at reducing the allergenicity of treatment preparations, whilst maintaining immunogenicity, have been described. Physical modification of allergen molecules may reduce or eliminate IgE reactivity and thus allergenicity (4). Such approaches have taken many forms including chemical modification, conjugation with synthetic bacterial DNA motifs, point mutations in native allergen gene sequences and the use of allergen multimers, fragments and peptides of various lengths. The use of soluble, short synthetic peptides for the treatment of allergic disease allows the delivery of T-cell epitopes of the allergen in an adjuvant-free, tolerogenic form, whilst avoiding IgE-mediated allergic reactions (5, 6). Synthetic peptides have been developed and evaluated in both experimental animal models and human clinical studies. Synthetic peptides are defined active pharmaceutical ingredients (API) and can be produced in a reproducible and standardized fashion that cannot be achieved with allergen extracts. Further advantages include low production costs, ease of purification and good stability in lyophilized form without the need for cold storage. Presentation of T-cell epitopes to T cells by nonprofessional antigen-presenting cells (APC) results in the induction of 'anergy', a term describing antigen-specific nonresponsive- AbstractSpecific allergen immunotherapy is clinically effective and disease modifying. It has a duration of effect that exceeds the treatment period and prevents both the progression of allergic rhinitis to asthma and the acquisition of new allergic sensitizations. However, immunotherapy is associated with a high frequency of adverse events related to ...
Inflammation is a hallmark of many airway diseases. Improved understanding of the cellular and molecular mechanisms of airway disease will facilitate the transition in our understanding from phenotypes to endotypes, thereby improving our ability to target treatments based on pathophysiologic characteristics. For example, allergic asthma has long been considered to be driven by an allergen-specific T helper 2 response. However, clinical and mechanistic studies have begun to shed light on the role of other cell subsets in the pathogenesis and regulation of lung inflammation. In this review, we discuss the importance of different lymphocyte subsets to asthma and other airway diseases, while highlighting the growing evidence that asthma is a syndrome that incorporates many immune phenotypes.
These observations suggest that immune tolerance induced by peptide immunotherapy can be used experimentally to treat an allergic response to another allergen and that the molecular mechanisms underlying induction of tolerance to a treatment-specific allergen and a bystander allergen might be different.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.